List of Excipients in Branded Drug DIFLORASONE DIACETATE

« Back to Dashboard

Generic Drugs Containing DIFLORASONE DIACETATE

Company	Ingredient	NDC	Excipient
E Fougera & Co a division of Fougera Pharmaceuticals Inc	diflorasone diacetate	0168-0243	GLYCERYL MONOSTEARATE
E Fougera & Co a division of Fougera Pharmaceuticals Inc	diflorasone diacetate	0168-0243	PETROLATUM
E Fougera & Co a division of Fougera Pharmaceuticals Inc	diflorasone diacetate	0168-0243	PROPYLENE GLYCOL
E Fougera & Co a division of Fougera Pharmaceuticals Inc	diflorasone diacetate	0168-0353	CETYL ALCOHOL
E Fougera & Co a division of Fougera Pharmaceuticals Inc	diflorasone diacetate	0168-0353	MINERAL OIL

What are the Most Frequently-Used Excipients in DIFLORASONE DIACETATE?

# Of NDCs	Excipient
2	BUTYLATED HYDROXYTOLUENE
3	CETYL ALCOHOL
2	CITRIC ACID MONOHYDRATE
8	GLYCERYL MONOSTEARATE
2	ISOPROPYL MYRISTATE

Diflorasone Diacetate Excipient Strategy and Commercial Opportunities

Last updated: October 1, 2026

Diflorasone diacetate is a potent topical corticosteroid with commercial opportunity in differentiated creams, ointments, lotions, and other topical semisolid dosage forms. The most attractive strategy is not a new-molecule patent play. It is a formulation, manufacturing, packaging, and lifecycle-management strategy focused on skin tolerability, application convenience, bioequivalence, and supply reliability.

The reference product category includes 0.05% diflorasone diacetate cream and ointment. Existing products use conventional petrolatum-based and oil-in-water semisolid vehicles. A sponsor can create value through improved spreadability, reduced greasiness, controlled drug release, preservative minimization, package usability, and targeted delivery to psoriasis, atopic dermatitis, and other corticosteroid-responsive dermatoses.

What is diflorasone diacetate and how is it used?

Diflorasone diacetate is a fluorinated topical corticosteroid indicated for corticosteroid-responsive dermatoses. It is generally positioned as a high-potency or super-high-potency topical steroid depending on dosage form, formulation, and potency classification system.

Attribute	Description
Active ingredient	Diflorasone diacetate
Common strength	0.05% w/w
Route	Topical dermatologic
Dosage forms	Cream and ointment
Therapeutic category	Topical corticosteroid
Primary indications	Psoriasis, atopic dermatitis, and other corticosteroid-responsive dermatoses
Regulatory pathway	Abbreviated New Drug Application for generic products; 505(b)(2) may support differentiated formulations
Biosimilar exposure	None; diflorasone diacetate is a small molecule
Main commercial constraints	Potency, local tolerability, semisolid bioequivalence, labeling restrictions, and generic price competition

Product labeling generally limits duration and treated surface area because prolonged exposure to potent topical corticosteroids increases the risk of systemic absorption, skin atrophy, striae, hypothalamic-pituitary-adrenal-axis suppression, and other adverse effects. Pediatric use requires particular caution because children have a higher body-surface-area-to-weight ratio.[1]

What excipients are used in diflorasone diacetate formulations?

The commercial excipient strategy is dosage-form specific. Ointments maximize occlusion and emolliency. Creams improve cosmetic acceptability and patient adherence.

Diflorasone diacetate cream excipients

Representative diflorasone diacetate cream formulations use:

• Cetostearyl alcohol
• Glyceryl monostearate
• Isopropyl myristate
• Polysorbate 60
• Propylene glycol
• Purified water
• Sodium citrate
• Stearic acid

These ingredients create an oil-in-water emulsion. Cetostearyl alcohol and glyceryl monostearate provide structure and viscosity. Isopropyl myristate improves spreadability and skin feel. Polysorbate 60 supports emulsification. Propylene glycol can act as a humectant, solvent, and penetration-enhancing excipient. Sodium citrate supports pH control.[2]

The principal formulation risks are phase separation, viscosity drift, microbial contamination, preservative performance, and changes in drug partitioning between the vehicle and skin.

Diflorasone diacetate ointment excipients

Representative ointment formulations use:

• Mineral oil
• White petrolatum

A petrolatum/mineral-oil vehicle is highly occlusive and supports treatment of dry, thickened, or lichenified lesions. It can increase hydration of the stratum corneum and potentially enhance corticosteroid penetration. The tradeoff is poor cosmetic acceptability, greasiness, staining of clothing, and lower patient preference for daytime use.[3]

Why the excipient system matters

Diflorasone diacetate has low aqueous solubility and is delivered into and through the stratum corneum from a semisolid vehicle. Excipients affect:

1. Drug thermodynamic activity.
2. Drug release from the formulation.
3. Partitioning into the stratum corneum.
4. Skin hydration and occlusion.
5. Spreadability and residence time.
6. Local irritation and sensitization.
7. Preservative performance.
8. Product stability and package compatibility.

A formulation that increases penetration may improve local efficacy but also increase the risk of irritation, atrophy, and systemic exposure. The commercial objective is controlled delivery, not maximum penetration.

What excipient strategy is best for diflorasone diacetate?

The strongest development strategy is a platform approach with separate vehicles for distinct patient and lesion needs.

Formulation concept	Commercial rationale	Principal development risk
Low-grease cream	Better daytime adherence and broader patient acceptance	Lower occlusion and possible changes in drug release
Petrolatum ointment	Strong occlusion for dry or thick plaques	Greasiness and poor cosmetic acceptance
Emollient-rich cream	Supports barrier comfort and reduced dryness	Higher complexity and preservative burden
Anhydrous ointment	Simple composition and low microbial risk	Poor washability and limited patient preference
Lotion or solution	Hair-bearing areas and larger surfaces	Higher evaporation and dose-uniformity risk
Foam or spray	Convenient application and differentiated positioning	Device, flammability, propellant, and CMC complexity
Hydrogel	Cooling feel and non-greasy profile	Potentially difficult solubilization and lower retention
Water-in-oil cream	Increased occlusion with improved spreadability	More difficult manufacturing and stability control

The most practical near-term opportunity is a cosmetically improved cream using a low-irritancy emulsion system. A second opportunity is an anhydrous ointment designed for sensitive skin and preservative avoidance. Foam, spray, and hydrogel products offer greater differentiation but face more demanding regulatory and manufacturing requirements.

What formulation patents could protect a diflorasone diacetate product?

Formulation patent protection would likely focus on the composition, manufacturing process, delivery device, or a defined clinical use rather than the active molecule.

Potential patent claim areas

A sponsor could pursue claims covering:

• Specific oil-to-water ratios.
• Defined particle-size distribution of diflorasone diacetate.
• Supersaturated or partially supersaturated systems.
• Anhydrous vehicles with controlled drug release.
• Low-irritancy emulsifier systems.
• Preservative-free multidose packaging.
• Metered-dose topical delivery.
• Foam or aerosol composition.
• Enhanced skin deposition with limited systemic absorption.
• Combination therapy with a barrier-repair ingredient.
• Manufacturing processes that control polymorph, particle size, or drug dispersion.
• Packaging systems that limit evaporation or oxidation.

Patent strength would depend on the difference between the proposed composition and known topical corticosteroid vehicles. Broad claims covering petrolatum, mineral oil, propylene glycol, fatty alcohols, or conventional emulsifiers would face substantial prior-art exposure. Narrow claims tied to measurable performance, such as a defined release profile, skin-deposition profile, stability result, or device-dose uniformity, would be more defensible.

The active-ingredient composition itself is old. Commercial exclusivity therefore depends primarily on formulation patents, method-of-use patents, regulatory exclusivity, manufacturing know-how, and brand differentiation.

When does diflorasone diacetate lose exclusivity?

Diflorasone diacetate has been marketed for decades, and basic active-ingredient patent protection is not the principal barrier to generic entry. The relevant competitive framework is generic availability, Orange Book-listed patents for specific branded products, and any product-specific regulatory exclusivity.

Exclusivity category	Expected significance for diflorasone diacetate
Original active-ingredient patent	Generally expired or commercially irrelevant
New chemical entity exclusivity	Not applicable to current products
Small-molecule formulation patents	Potentially relevant for a particular product
Method-of-use patents	Possible, but narrow and vulnerable to design-around
Pediatric exclusivity	Product-specific; should be verified in the current FDA record
Orphan exclusivity	Not applicable to the ordinary dermatologic indications
Generic competition	Established risk for conventional cream and ointment products

Patent expiry cannot be assigned reliably from the ingredient name alone because expiration depends on the specific NDA, formulation, patent listing, patent-term adjustment, patent-term extension, and jurisdiction. For a branded or reformulated product, the current FDA Orange Book entry and relevant patent records control the analysis.[4]

What is the Orange Book status of diflorasone diacetate?

The Orange Book is relevant only to approved drug products and listed patents associated with specific applications. Generic diflorasone diacetate products may reference a listed reference product without carrying meaningful patent protection of their own.

For an investment or launch analysis, the sponsor should distinguish:

1. The reference listed drug.
2. The exact dosage form and strength.
3. The application holder.
4. Any active listed patents.
5. The therapeutic-equivalence code.
6. The commercial status of the reference product.
7. Whether the reference product is currently marketed.

A conventional 0.05% cream or ointment is generally a mature generic opportunity. A new foam, spray, lotion, or device-enabled presentation may require a separate regulatory and patent analysis because it may not be substitutable with an existing cream or ointment.

Which companies are challenging diflorasone diacetate products?

The market is primarily exposed to generic manufacturers rather than biosimilar developers. Potential competitors include established topical-generic companies, contract manufacturers, and dermatology-focused specialty-pharmaceutical companies.

The relevant competitor groups are:

• Manufacturers of generic 0.05% cream.
• Manufacturers of generic 0.05% ointment.
• Companies with dermatology semisolid manufacturing capacity.
• Contract development and manufacturing organizations with topical IVRT and IVPT capability.
• Specialty companies developing alternative topical corticosteroid vehicles.
• Digital dermatology companies using established topical actives in differentiated packaging or treatment programs.

Specific Paragraph IV litigation cannot be inferred from the active ingredient alone. It must be tied to a particular abbreviated application and listed patent. For a mature active ingredient with conventional cream and ointment products, the larger commercial risk is often rapid ANDA entry and price erosion rather than a prolonged patent challenge.

What FDA regulatory strategy applies to a new diflorasone diacetate formulation?

A conventional generic cream or ointment would normally pursue an ANDA referencing the applicable reference product. A materially different dosage form, strength, delivery system, or clinical positioning may require a 505(b)(2) application.

ANDA strategy

The ANDA route is most appropriate when the proposed product matches the reference product in:

• Active ingredient.
• Strength.
• Dosage form.
• Route of administration.
• Conditions of use.
• Labeling, subject to permitted differences.

For topical semisolid products, development increasingly depends on comparative quality and performance data. Relevant testing can include:

• Qualitative sameness of inactive ingredients.
• Quantitative sameness where required.
• Comparative rheology.
• Globule or particle-size distribution.
• pH and viscosity.
• IVRT.
• IVPT where applicable.
• Microstructure.
• In-use stability.
• Preservative effectiveness.
• Container-closure compatibility.

FDA guidance on topical products emphasizes that formulation composition and product microstructure can materially affect performance. A sponsor that changes the excipient system should expect a more demanding comparability package.[5]

505(b)(2) strategy

A 505(b)(2) application may be appropriate for:

• A foam.
• A spray.
• A lotion.
• A novel delivery device.
• A new concentration.
• A materially different vehicle.
• A new indication.
• A formulation with clinical advantages that cannot be supported through ordinary generic equivalence.

This pathway can support product-specific patent protection, but it also increases clinical, CMC, and regulatory cost.

What commercial opportunities exist for diflorasone diacetate?

1. Cosmetic improvement

A low-grease cream with rapid rub-in, low residue, and reduced odor could improve adherence without changing the active ingredient. This is the most accessible commercial opportunity.

2. Preservative-minimized products

A preservative-free or low-preservative product could target patients with sensitive skin or repeated exposure concerns. Multidose packaging must prevent microbial contamination, and the absence of a conventional preservative does not eliminate the need for robust microbiological control.

3. Targeted lesion treatment

An ointment optimized for thick plaques and an emulsion optimized for inflamed, less-dry lesions could support portfolio segmentation. The products would need clear labeling and differentiated user instructions.

4. Hair-bearing-area delivery

A lotion, solution, foam, or spray could improve application to the scalp and other hair-bearing areas. This opportunity is commercially attractive but technically harder because dose delivery, evaporation, flammability, and packaging become central issues.

5. Combination and barrier-repair products

A corticosteroid combined with a moisturizer or barrier-supporting excipient may improve tolerability and adherence. However, combination products can create regulatory and patent complications. A simple co-pack or regimen-based strategy may be easier than a single combined product.

6. Contract manufacturing and private-label supply

Topical semisolid capacity is a commercial opportunity in its own right. Manufacturers with validated ointment and emulsion platforms, tube-filling capability, and dermatology analytical testing can supply multiple sponsors with limited changes to core equipment.

How strong is the diflorasone diacetate patent estate?

The estate is likely weak around the active ingredient and stronger only where a sponsor develops a genuinely differentiated product. The most defensible assets would combine composition claims with process controls and demonstrated performance.

Asset type	Strategic strength
Diflorasone diacetate molecule	Low
Conventional petrolatum ointment	Low
Conventional oil-in-water cream	Low to moderate
Novel foam or device	Moderate to high
Defined microstructure and release profile	Moderate
Manufacturing process with reproducible performance	Moderate
Preservative-free package system	Moderate
Narrow method-of-use claim	Variable
Trade secret manufacturing know-how	Potentially high

Trade secrets may provide more practical value than patents for mixing sequence, temperature control, drug dispersion, deaeration, filling, and scale-up. These controls can reduce batch variability and support regulatory approval even when they do not prevent competitors from launching.

What generic launch risks exist?

The main launch risks are:

• Failure to match the reference product’s microstructure.
• Inadequate IVRT or IVPT performance.
• Drug crystallization during storage.
• Phase separation or viscosity drift.
• Preservative failure.
• Tube or pump incompatibility.
• Poor patient acceptance of greasiness.
• Limited manufacturing capacity for dermatology semisolids.
• Rapid price erosion after multiple ANDA approvals.
• Labeling limitations associated with high-potency corticosteroid use.
• State substitution rules and payer preference for low-cost generic products.

A differentiated product should therefore avoid competing only on active-ingredient price. The stronger proposition is a measurable improvement in application, tolerability, dosing convenience, or supply continuity.

Key Takeaways

• Diflorasone diacetate is a mature topical corticosteroid with no meaningful biosimilar risk.
• The principal opportunity is formulation differentiation, not new-molecule exclusivity.
• Petrolatum/mineral-oil ointments maximize occlusion but have cosmetic disadvantages.
• Oil-in-water creams offer better usability but require tighter control of emulsion structure, preservation, and release.
• The most practical product opportunity is a cosmetically improved cream or preservative-minimized ointment.
• Foams, sprays, lotions, and device-enabled products offer greater differentiation but likely require a more complex regulatory pathway.
• Conventional formulation claims face substantial prior-art pressure.
• Manufacturing know-how, package design, and performance data may be more valuable than broad composition patents.
• Generic price erosion is the central commercial risk for standard 0.05% cream and ointment products.
• Current Orange Book entries, application-specific patents, and Paragraph IV records must be evaluated at the product level.

FAQs

Is diflorasone diacetate a high-potency corticosteroid?

Yes. Diflorasone diacetate is a potent topical corticosteroid, with potency affected by concentration, vehicle, dosage form, and classification methodology.

Can diflorasone diacetate be formulated as a foam?

Yes, technically. A foam could improve scalp and hair-bearing-area application, but it would introduce device, propellant, flammability, dose-uniformity, and regulatory requirements.

Which excipients best improve diflorasone diacetate skin penetration?

Propylene glycol, isopropyl myristate, occlusive hydrocarbons, and selected emulsifiers can affect penetration. The optimal system must balance skin deposition against irritation and systemic absorption.

Is a preservative-free diflorasone diacetate cream commercially feasible?

Yes, but feasibility depends on packaging, water activity, manufacturing controls, in-use stability, and microbiological testing. Airless or unit-dose packaging may support the strategy.

Is a new diflorasone diacetate formulation eligible for a 505(b)(2) application?

Potentially. A materially different dosage form, delivery system, concentration, or clinical use may support a 505(b)(2) pathway rather than a conventional ANDA, subject to FDA review.

References

1. U.S. Food and Drug Administration. (n.d.). Diflorasone diacetate cream and ointment prescribing information. DailyMed.

2. National Library of Medicine. (n.d.). Diflorasone diacetate cream: Inactive ingredients and product labeling. DailyMed.

3. National Library of Medicine. (n.d.). Diflorasone diacetate ointment: Inactive ingredients and product labeling. DailyMed.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.

5. U.S. Food and Drug Administration. (2022). Physicochemical and structural (Q3) characterization of topical drug products submitted in ANDAs: Draft guidance for industry. FDA.